|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Watson PA, Arora VK and Sawyers CL:
Emerging mechanisms of resistance to androgen receptor inhibitors
in prostate cancer. Nat Rev Cancer. 15:701–711. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pettersson F, Del Rincon SV and Miller WH
Jr: Eukaryotic translation initiation factor 4E as a novel
therapeutic target in hematological malignancies and beyond. Expert
Opin Ther Targets. 18:1035–1048. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Spilka R, Ernst C, Mehta AK and Haybaeck
J: Eukaryotic translation initiation factors in cancer development
and progression. Cancer Lett. 340:9–21. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pelletier J, Graff J, Ruggero D and
Sonenberg N: Targeting the eIF4F translation initiation complex: A
critical nexus for cancer development. Cancer Res. 75:250–263.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Siddiqui N and Sonenberg N: Signalling to
eIF4E in cancer. Biochem Soc Trans. 43:763–772. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bitting RL and Armstrong AJ: Targeting the
PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
Endocr Relat Cancer. 20:R83–R99. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kremer CL, Klein RR, Mendelson J, Browne
W, Samadzedeh LK, Vanpatten K, Highstrom L, Pestano GA and Nagle
RB: Expression of mTOR signaling pathway markers in prostate cancer
progression. Prostate. 66:1203–1212. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Graff JR, Konicek BW, Vincent TM, Lynch
RL, Monteith D, Weir SN, Schwier P, Capen A, Goode RL, Dowless MS,
et al: Therapeutic suppression of translation initiation factor
eIF4E expression reduces tumor growth without toxicity. J Clin
Invest. 117:2638–2648. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mao B and Wang G: MicroRNAs involved with
hepatocellular carcinoma (Review). Oncol Rep. 34:2811–2820.
2015.PubMed/NCBI
|
|
12
|
Gambari R, Brognara E, Spandidos DA and
Fabbri E: Targeting oncomiRNAs and mimicking tumor suppressor
miRNAs: Νew trends in the development of miRNA therapeutic
strategies in oncology (Review). Int J Oncol. 49:5–32.
2016.PubMed/NCBI
|
|
13
|
Garzon R and Marcucci G: Potential of
microRNAs for cancer diagnostics, prognostication and therapy. Curr
Opin Oncol. 24:655–659. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ribas J, Ni X, Haffner M, Wentzel EA,
Salmasi AH, Chowdhury WH, Kudrolli TA, Yegnasubramanian S, Luo J,
Rodriguez R, et al: miR-21: An androgen receptor-regulated microRNA
that promotes hormone-dependent and hormone-independent prostate
cancer growth. Cancer Res. 69:7165–7169. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Eberlein C, Kendrew J, McDaid K, Alfred A,
Kang JS, Jacobs VN, Ross SJ, Rooney C, Smith NR, Rinkenberger J, et
al: A human monoclonal antibody 264RAD targeting αvβ6 integrin
reduces tumour growth and metastasis, and modulates key biomarkers
in vivo. Oncogene. 32:4406–4416. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fendler A, Jung M, Stephan C, Erbersdobler
A, Jung K and Yousef GM: The antiapoptotic function of miR-96 in
prostate cancer by inhibition of FOXO1. PLoS One. 8:e808072013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Qu F, Cui X, Hong Y, Wang J, Li Y, Chen L,
Liu Y, Gao Y, Xu D and Wang Q: MicroRNA-185 suppresses
proliferation, invasion, migration, and tumorigenicity of human
prostate cancer cells through targeting androgen receptor. Mol Cell
Biochem. 377:121–130. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang GM, Bao CY, Wan FN, Cao DL, Qin XJ,
Zhang HL, Zhu Y, Dai B, Shi GH and Ye DW: MicroRNA-302a suppresses
tumor cell proliferation by inhibiting AKT in prostate cancer. PLoS
One. 10:e01244102015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang K, Tang Y, He L and Dai Y:
MicroRNA-340 inhibits prostate cancer cell proliferation and
metastasis by targeting the MDM2-p53 pathway. Oncol Rep.
35:887–895. 2016.PubMed/NCBI
|
|
20
|
Shubbar E, Kovács A, Hajizadeh S, Parris
TZ, Nemes S, Gunnarsdóttir K, Einbeigi Z, Karlsson P and Helou K:
Elevated cyclin B2 expression in invasive breast carcinoma is
associated with unfavorable clinical outcome. BMC Cancer. 13:12013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Segura MF, Belitskaya-Lévy I, Rose AE,
Zakrzewski J, Gaziel A, Hanniford D, Darvishian F, Berman RS,
Shapiro RL, Pavlick AC, et al: Melanoma microRNA signature predicts
post-recurrence survival. Clin Cancer Res. 16:1577–1586. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Swierniak M, Wojcicka A, Czetwertynska M,
Stachlewska E, Maciag M, Wiechno W, Gornicka B, Bogdanska M,
Koperski L, de la Chapelle A, et al: In-depth characterization of
the microRNA transcriptome in normal thyroid and papillary thyroid
carcinoma. J Clin Endocrinol Metab. 98:E1401–E1409. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li T, Li D, Sha J, Sun P and Huang Y:
MicroRNA-21 directly targets MARCKS and promotes apoptosis
resistance and invasion in prostate cancer cells. Biochem Biophys
Res Commun. 383:280–285. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Reis ST, Pontes-Junior J, Antunes AA,
Dall'Oglio MF, Dip N, Passerotti CC, Rossini GA, Morais DR,
Nesrallah AJ, Piantino C, et al: miR-21 may acts as an oncomir by
targeting RECK, a matrix metalloproteinase regulator, in prostate
cancer. BMC Urol. 12:142012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang H, Guan M, Townsend KL, Huang TL, An
D, Yan X, Xue R, Schulz TJ, Winnay J, Mori M, et al: MicroRNA-455
regulates brown adipogenesis via a novel HIF1an-AMPK-PGC1α
signaling network. EMBO Rep. 16:1378–1393. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang Z, Hou C, Meng F, Zhao X, Zhang Z,
Huang G, Chen W, Fu M and Liao W: MiR-455-3p regulates early
chondrogenic differentiation via inhibiting Runx2. FEBS Lett.
589:3671–3678. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lalevée S, Lapaire O and Bühler M: miR455
is linked to hypoxia signaling and is deregulated in preeclampsia.
Cell Death Dis. 5:e14082014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rosenwald IB, Rhoads DB, Callanan LD,
Isselbacher KJ and Schmidt EV: Increased expression of eukaryotic
translation initiation factors eIF-4E and eIF-2 alpha in response
to growth induction by c-myc. Proc Natl Acad Sci USA. 90:6175–6178.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Andrieu C, Taieb D, Baylot V, Ettinger S,
Soubeyran P, De-Thonel A, Nelson C, Garrido C, So A, Fazli L, et
al: Heat shock protein 27 confers resistance to androgen ablation
and chemotherapy in prostate cancer cells through eIF4E. Oncogene.
29:1883–1896. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu F, Wang X, Li J, Gu K, Lv L, Zhang S,
Che D, Cao J, Jin S and Yu Y: miR-34c-3p functions as a tumour
suppressor by inhibiting eIF4E expression in non-small cell lung
cancer. Cell Prolif. 48:582–592. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jiang CC, Croft A, Tseng HY, Guo ST, Jin
L, Hersey P and Zhang XD: Repression of microRNA-768-3p by MEK/ERK
signalling contributes to enhanced mRNA translation in human
melanoma. Oncogene. 33:2577–2588. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yao YS, Qiu WS, Yao RY, Zhang Q, Zhuang
LK, Zhou F, Sun LB and Yue L: miR-141 confers docetaxel
chemoresistance of breast cancer cells via regulation of EIF4E
expression. Oncol Rep. 33:2504–2512. 2015.PubMed/NCBI
|
|
33
|
Graff JR, Konicek BW, Lynch RL, Dumstorf
CA, Dowless MS, McNulty AM, Parsons SH, Brail LH, Colligan BM, Koop
JW, et al: eIF4E activation is commonly elevated in advanced human
prostate cancers and significantly related to reduced patient
survival. Cancer Res. 69:3866–3873. 2009. View Article : Google Scholar : PubMed/NCBI
|
